Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

Inclusion Criteria:

- At least a 1-year history of CM consistent with a diagnosis according to the ICHD-3,
2018

- Age of the participant at the time of migraine onset < 50 years

- Confirmation of headache/migraine headache day frequency as follows:

1. History of, on average, ≥ 15 headache days per month in the 3 months prior to
Visit 1 in the opinion of the investigator AND

2. ≥ 15 headache days during the 4-week screening/baseline period per the electronic
diary (eDiary) AND

3. ≥ 8 days during the 4-week screening/baseline period that qualify as being a
migraine day per the eDiary

- Participants must be using a medically acceptable and effective method of birth
control during the course of the entire study,

Exclusion Criteria:

- Has a history of migraine, accompanied by diplopia or decreased level of
consciousness, or retinal migraine

- Has a current diagnosis of new persistent daily headache, trigeminal autonomic
cephalgia (eg, cluster headache), or painful cranial neuropathy

- History of an inadequate response to > 4 medications (2 of which have different
mechanisms of action) prescribed for the prevention of migraine

- Woman is pregnant, planning to become pregnant during the course of the study, or
currently lactating. Women of childbearing potential must have a negative urine
pregnancy test at Visit 1 and Visit 2.